Bio-Techne Corporation (TECH) Stock

Bio-Techne Corporation, along with its subsidiaries, specializes in the development, manufacturing, and global distribution of life science reagents, instruments, and services catering to both research and clinical diagnostic markets. Operating through two primary segments, Protein Sciences and Diagnostics and Genomics, the company offers a diverse range of products essential for advancing scientific discoveries and medical diagnostics.

Under its Protein Sciences segment, Bio-Techne focuses on biological reagents pivotal in life science research, diagnostics, and cell and gene therapy applications. These include cytokines, growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. The segment also provides sophisticated proteomic analytical tools designed for automated western blot and multiplexed ELISA workflows, offering both manual and automated protein analysis instruments and immunoassays for precise quantification of proteins in biological fluids.

Bio-Techne's Diagnostics and Genomics segment is dedicated to developing and manufacturing diagnostic products for regulated markets, encompassing controls, calibrators, and diagnostic assays. Additionally, the segment specializes in exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits tailored for research and clinical applications. The company's product offerings also extend to genetic carrier screening, oncology diagnostics, molecular controls, and research instruments used in hematology, blood chemistry, gases, and coagulation controls and reagents for various diagnostic applications. Bio-Techne operates under several well-established brands including R&D Systems, Tocris Biosciences, Novus Biologicals, ProteinSimple, Advanced Cell Diagnostics, Exosome Diagnostics, and Asuragen, reflecting its broad expertise and market presence in the life sciences sector.

Founded in 1976 and headquartered in Minneapolis, Minnesota, Bio-Techne Corporation continues to innovate and expand its portfolio, reinforcing its commitment to advancing scientific research and enhancing diagnostic capabilities globally.